當前位置：   首頁(yè) > 需求大廳

 >  生產(chǎn)研發(fā) 

 >  臨床試驗 

罕見(jiàn)癌癥研究基金會(huì )(RCRF),致力于通過(guò)戰略投資和創(chuàng )新合作進(jìn)行基礎治療罕見(jiàn)的癌癥,和美國文化募捐組織(ATCC),世界上最大的非營(yíng)利性細胞株庫,建立神經(jīng)內分泌腫瘤細胞株收集目錄。腸道良性腫瘤和胰腺神經(jīng)內分泌腫瘤(PNET)需求一種新療法的研究和發(fā)展，即在體內原發(fā)性腫瘤中建立新的細胞株。 為了刺激發(fā)展新的良性腫瘤和PNET細胞系,該基金會(huì )是高興地宣布第二次開(kāi)放競爭十個(gè)人獎項:開(kāi)發(fā)人員的第一個(gè)新的細胞系在每個(gè)疾病(腸道良性腫瘤和PNET)將獲得100000美元，開(kāi)發(fā)者的第二,第三,第四,第五個(gè)新細胞系在每個(gè)疾病將會(huì )收到50000美元。原文如下：https://www.innocentive.com/ar/challenge/9933756 The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Caring for Carcinoid Foundation therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery. Source: InnoCentive Challenge ID: 9933756 Challenge Overview This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use. To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual   [更多]

彌漫性大B細胞淋巴瘤(DLBCL)是一種最常見(jiàn)的非霍奇金淋巴瘤，診斷病例在美國約占淋巴瘤的30%。它是一種特異質(zhì)性疾病。由于臨床多樣性和復雜性,又有新的突變在某些難治性患者身上被發(fā)現。阿斯利康需要創(chuàng )建一種彌漫性巨大B細胞淋巴瘤的合適的臨床模型。 具體鏈接在：https://www.innocentive.com/ar/challenge/9933016 AstraZeneca Challenge: Developing Clinically-Relevant Models for Diffuse Large B Cell Lymphoma (DLCBL) TAGS: AstraZeneca, Physical Sciences, Life Sciences, Nature, Requests for Partners and Suppliers, Chemistry, RTP AWARD: See details | DEADLINE: 6/02/15 | ACTIVE SOLVERS: 9 | POSTED: 3/04/15 Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and accounts for up to 30% of newly diagnosed cases in the United States. It is a heterogeneous disease which in part appears to be driven by chronic activation of key survival pathways. A limited number of DLBCL cell lines are available, however there are gaps, and specific patient subtypes are not represented. To add to the complexity of clinical diversity, new mutations are being identified in certain treatment-resistant patients. AstraZeneca is interested in innovative proposals to create suitable preclinical models of DLBCL. This is a Reduction-to-Practice Challenge that requires a written proposal and experimental proof-of-concept data (and/or sample delivery). The Challenge has a special award structure. Whether creating a model for DLBCL or a model of acquired resistance to ibrutinib, up to $10,000 will be designated for solutions that highlight novel technologies to generate in vitro cell lines, whereas up to $25,000 will be awarded for submissions that successfully utilize patient-derived tissues.   [更多]

肝臟疾病是一種由病毒或有毒物連續侵害造成肝臟晚期纖維化的慢性疾病。目前，我們的治療方法很有限，尋找治療方法的大多數臨床試驗都失敗了，部分原因是由于缺乏預測肝臟疾病發(fā)展的生物標志物。公司需要尋找一種新的生物標志物，對提高疾病的可控性會(huì )有很大的幫助，定期監測生物標志物也可以促進(jìn)臨床試驗治療藥物的進(jìn)一步發(fā)展。 具體可以查看https://www.innocentive.com/ar/challenge/9933671 Challenge Overview Liver disease represents a worldwide unmet medical need. Although there are various causes, the danger is that the liver will become so damaged that it can no longer function adequately. Whether the insult is a viral infection, chemical injury, or immune-related, liver disease follows a slow and steady progression. Early stage liver disease is characterized by inflammation, which if left untreated, can cause scarring and fibrosis. A healthy liver is capable of repair and regeneration, but when there are architectural changes to the tissue, the damage can no longer be reversed. Biopsies are routinely conducted to diagnose liver fibrosis and cirrhosis. Undergoing this invasive procedure involves significant abdominal pain along with the risk for complications and sampling error. Therefore, many patients are reluctant to have a second biopsy even when it is medically advisable. The Seeker desires a specific and sensitive biomarker(s) that is highly associated with liver fibrosis and could be used as a surrogate for clinical efficacy and ideally, could guide treatment selection. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 17, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, as further described in the Challenge-Specific Agreement, Solvers will grant to the Seeker a one hundred and eighty (180)-day Exclusivity Period from the deadline [11:59 PM (US Eastern Time) on August 17, 2015] for a non-exclusive   [更多]

我們體內以分泌胰島素來(lái)維持胰島細胞血糖水平和體內平衡。而糖尿病患者的胰島細胞是缺乏或無(wú)效的。沒(méi)有足夠活性的胰島素，糖尿病患者就無(wú)法控制血糖。胰島移植是一種治療策略,糖尿病患者需要胰島素注射來(lái)控制他們的疾病，減輕或根除癥狀。阿斯利康正在尋找一個(gè)簡(jiǎn)單的裝置將人類(lèi)胰島移植出來(lái)，來(lái)檢測藥物的性能。 具體如下網(wǎng)站，https://www.innocentive.com/ar/challenge/9933735 Pancreatic islet beta-cells sense blood sugar levels and secrete insulin to maintain homeostasis. In patients with diabetes, islet beta-cells are either lacking or ineffective. Islet transplantation is a treatment strategy that allows diabetics to reduce or eliminate the need for insulin injections to control their disease. AstraZeneca is searching for a simple device to transplant human islets to facilitate testing of therapeutic agents. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933735 Challenge Overview Diabetes is a disease of the pancreatic islet cells. Of the four cell types, insulin-producing beta-cells are the most abundant. Without adequate levels of insulin, diabetes patients have difficulty controlling their blood sugar. One alternative to self-administration of medicine is islet transplantation. The procedure involves an infusion of isolated donor islets into the patient. If the graft is accepted, these islets will function to regulate blood glucose levels through the production of insulin. AstraZeneca is searching for a simple device for the transplantation and subsequent retrieval of human islets to support in vivo testing of therapeutic agents. ABOUT THE SEEKER AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical   [更多]

濕疹是一種慢性皮膚疾病，包括炎癥，紅腫，癢。許多非處方藥品都是從干燥的角度來(lái)治療濕疹的，南昌我們需要處方藥物，減輕瘙癢和炎癥的癥狀?，F在尋求開(kāi)發(fā)一種用于治療濕疹的新的解決方案。具體如下：（https://www.innocentive.com/ar/challenge/9933668?challenge=9933668） TAGS: Chemistry, Requests for Partners and Suppliers, Life Sciences, Ideation AWARD: $15,000 USD | DEADLINE: 1/31/15 | ACTIVE SOLVERS: 55 | POSTED: 12/09/14 Eczema is a term that refers to a group of chronic skin conditions that involve inflammation, irritation, and itch. Many over-the-counter products are marketed to persons with eczema for the purpose of gaining relief from the dry, itchy rash. Flare-ups require prescription medications that alleviate the symptoms of itch and inflammation. The Seeker is looking to develop novel solutions for the treatment of eczema. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. Source: InnoCentive Challenge ID: 9933668 Challenge Overview Eczema is a general term for all types of dermatitis. The etiology of eczema remains unknown, although there is evidence to suggest that the cause may be hereditary or linked to environmental triggers. People try many things to treat their eczema and these include over-the-counter remedies, prescription medications, and alternative therapies. Common complaints about these treatments stem from the lack of effectiveness in providing symptom relief. Topical corticosteroids and calcineurin inhibitors are widely used to effectively alleviate itch and inflammation, however, prolonged and inappropriate use can cause permanent changes to the skin such as skin thinning. Therefore, eczema treatment remains an unmet medical need. The Seeker is an independent, research-based pharmaceutical company that desires novel ideas for molecules, which are targeted for other diseases, but may also prove to be beneficial for eczema patients. This is an Ideation Challenge, which has the following unique features: There is a guaranteed award. The awards will be paid to the best   [更多]

勃林格殷格翰公司對診斷和治療慢性阻塞性肺疾病以及重癥哮喘患者新方法非常感興趣。針對慢性阻塞性肺病患者或重癥哮喘所造成的呼吸道障礙，他們積極尋求恢復方法并尋找分子靶點(diǎn)開(kāi)發(fā)治療藥物。具體如下：（https://www.innocentive.com/ar/challenge/9933560） Boehringer Ingelheim (the Seeker) is interested in identifying new therapeutic concepts for the treatment of patients with chronic obstructive pulmonary disease (COPD) or severe asthma. The Seeker is specifically searching for molecular targets to develop therapeutic agents for the restoration of the airway epithelial barrier function in patients with COPD or severe asthma. The Seeker is also interested in molecular targets driving the regeneration of the airway epithelium. Submitted solutions that meet the Solution Requirements according to this InnoCentive Challenge Statement will be considered for up to three awards of $15,000 each. However, the Seeker may (i) not award any solution if none of the submitted proposals meets all Solution Requirements or (ii) award only the solution of the highest overall quality with $15,000. The consideration for an award requires the willingness and ability of the Solver to provide the Seeker with a non-exclusive license regarding all intellectual property related to the Challenge according to the terms of the InnoCentive Theroretical (Non-Exclusive-License) Challenge-Specific Agreement. 2. Additional application for Research Funding In addition to consideration for the award(s) Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute a research plan that is proposed in the submitted solution. The requested funding should not exceed a funding period of 2 years and a total budget of $200,000. The selection of candidates for Research Funding will be conducted after completion of the Challenge, and will require the submission of additional information. The decision to fund research will be at the sole discretion of the Seeker. The Challenge according to No.   [更多]

目前，科學(xué)家們只能很有限的預測藥物不同配方的生物利用度。盡管有廣闊的臨床前數據的藥物，我們利用已知的分子性質(zhì)和制劑在體內的數據并不能完全預測到藥物的溶解性能，使得藥品在體內部分的變化引起整個(gè)研究項目的變化。需求者對兩種配方的10個(gè)不同的藥物分子已經(jīng)收集了大量在體外和體內的數據，現在尋求一種模型，能夠使用體外數據和僅有的的物化性質(zhì)預測不同制劑在體內的性能。具體如下：（https://www.innocentive.com/ar/challenge/9933559） The Seeker is looking for ideas on how to use a variety of properties of molecules, and simple laboratory tests on different formulations to predict the change in a drug’s pharmacokinetic performance in biological systems resulting from different formulations. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. Source: InnoCentive Challenge ID: 9933559 Challenge Overview Currently, scientists possess a limited ability to predict the bioavailability of different formulations of drugs despite vast pre-clinical data for the drugs. Utilizing measured properties of molecules and the dissolution performance of formulations to predict in vivo data is complex, and made more so by the inherent variability of in vivo data due partly to the variability of the test subjects. The Seeker has collected a significant amount of in vitro and in vivo data for two formulations each of 10 different molecules and would like Solvers to present ideas on how to use the in vitro data and simple molecular descriptors to predict the in vivo performance of different formulations. This is an Ideation Challenge, which has the following unique features: There is a guaranteed award. The awards will be paid to the best submission(s) as solely determined by the Seeker. The total payout will be $15,000, with at least one award being no smaller than $5,000 and no award being smaller than $1,000. Submission forwarding occurs during the Challenge. Since submissions will be forwarded to the Seeker throughout the Challenge, please make sure you upload only a finished proposal. You can submit an updated version of your proposal only as a new submission. If you submit an updated version of your proposal,   [更多]

不能控制其發(fā)作的癲癇猝死（SUDEP）是導致年輕人死亡的主要原因。每年超過(guò)千分之一的癲癇患者死于猝死，如果是不受控制的癲癇發(fā)作，風(fēng)險會(huì )增加一百五十分之一。一種普遍恐懼的意識和持續受到的歧視導致太多的人隱藏自己的癲癇病情而沒(méi)有接受持續治療或尋求更有效的治療方法。這增加了他們癲癇猝死的風(fēng)險 癲癇基金會(huì )幫助機構決心改變這種狀況，開(kāi)展一個(gè)創(chuàng )意的宣傳活動(dòng)，鼓勵人們尋求最佳的癲癇發(fā)作和癲癇發(fā)作控制和教育他們自己和他們的家庭以及他們如何可以減輕癲癇猝死的風(fēng)險。此外，這個(gè)活動(dòng)應該邀請更廣泛的醫療保健社區討論SUDEP，明白不接受持續發(fā)作的重要性，并尋找一種更有效的治療方法。具體（https://www.innocentive.com/ar/challenge/9933717）如下 TAGS: Global Health, Business/Entrepreneurship, Life Sciences, Scientific American, Ideation AWARD: $15,000 USD | DEADLINE: 7/13/15 | ACTIVE SOLVERS: 12 | POSTED: 6/09/15 Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in young adults who have epilepsy and cannot control their seizures. Each year, more than 1 out of 1,000 people with epilepsy die from SUDEP, and, if seizures are uncontrolled, the risk increases to more than 1 out of 150. A widespread lack of awareness and ongoing fear and discrimination lead too many individuals to hide their epilepsy and to accept ongoing seizures instead of seeking out more effective treatments. This increases their risk of SUDEP. The Epilepsy Foundation SUDEP Institute is determined to change this and is challenging Solvers to come up with ideas for a creative advocacy campaign that encourages people with seizures and epilepsy to seek optimal seizure control and to educate themselves and their families about SUDEP and how they can mitigate its risks. In addition, the campaign should invite the broader health care community to talk about SUDEP, understand the importance of not accepting ongoing seizures, and pursue all effective treatment options. Can you help us to demystify seizures and epilepsy, and empower people with epilepsy? This is an Ideation Challenge with a guaranteed award for at least one submitted solution.   [更多]

我們對治療克羅恩病和潰瘍性結腸炎的新的機理和作用點(diǎn)感興趣，這些可能包括，但不限于，接近病灶或調節菌群，代謝，遺傳，后天產(chǎn)生的抗體。新治療方法可能包括，但不限于，疫苗，基因治療，和小分子化合物，而免疫抑制除外。理想的途徑是先找到IBD發(fā)病新機理，再轉化為一種治療新的方法。具體如下：（https://www.innocentive.com/ar/challenge/9933446） Novel Treatment Approaches to Cure Inflammatory Bowel Diseases TAGS: Nature, Chemistry, Life Sciences, Ideation AWARD: $10,000 USD | DEADLINE: 2/16/15 | ACTIVE SOLVERS: 21 | POSTED: 12/16/14 The Seeker for this Challenge desires proposals describing potential approaches for curing Crohn’s disease and ulcerative colitis. The Seeker is interested in novel mechanisms of action that specifically address the pathogenesis of inflammatory bowel diseases (IBD). These may include, but are not limited to, approaches targeting or modulating the microbiota, metabolism, genetic, and epigenetic targets. Platforms may involve, but are not limited to, vaccines, gene therapy, and small molecule compounds. The Seeker is not interested in immunosuppression. Desirable approaches are specifically relevant to the pathogenesis of IBD and can be translated into a cure. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. In addition to the Challenge award, the Seeker is open to establishing potential collaborations with the winning Solver(s) to further investigate proposed mechanisms with the eventual goal of developing a cure for IBD. Source: InnoCentive Challenge ID: 9933446 Challenge Overview The Seeker for this Challenge desires proposals for novel approaches that specifically address the causes of inflammatory bowel diseases (IBD) to enable the development of a cure. The Seeker is interested in unique ideas and new approaches (including gene delivery techniques), but is not interested in approaches that are simply common targets for various immunological conditions. That is, the approach must be specifically relevant to the pathogenesis of IBD and can be translated into a cure. This is an Ideation Challenge, which has   [更多]

截止日期：2014年12月31日 已有提案：17件 發(fā)布時(shí)間：2014年11月18日 已選0個(gè)，還需要1個(gè)。 具體要求：研究人員需要尋找一種新植入盆腔器官脫垂的治療方法。這一懸賞只需要一個(gè)書(shū)面建議。 以下幾條信息必須同時(shí)滿(mǎn)足: 1. 必須在2014年12月31日下午11時(shí)59分（美國東部時(shí)間）收到，逾期的投標概不受理。只需要提案人一個(gè)書(shū)面建議提交。解決方領(lǐng)取獎金的同時(shí)，必須將其獨有的知識產(chǎn)權（IP）的權利轉讓給舉辦方。 2.這個(gè)懸賞任務(wù)是必須尋找一種尋找新植入盆腔器官脫垂的治療方法。盆腔器官脫垂（POP）是指盆腔器官（膀胱，子宮和直腸）的下降，是由于周?chē)Y構支撐的損壞。最近的研究表明，婦女在她們的一生中有12.6％的可能性接受手術(shù)治療脫垂修復。POP手術(shù)修復的目的是提供并改善盆腔器官的功能，同時(shí)盡量減少復發(fā)。然而，網(wǎng)狀增強修復有可能需要再次手術(shù)，在5年目并發(fā)癥的婦女6％，約10％將需要再次手術(shù)治療復發(fā)性脫垂。所以我們需要一種更好治療方法才能實(shí)現不復發(fā)的目標。3、投稿在此網(wǎng)站：https://www.innocentive.com/ar/challenge/9933488   [更多]